Immuno-oncology

MD IQ

Conference Coverage

Nivo/ipi shrinks early NSCLC before surgery

CHICAGO – Among patients who went on to resection, 44% of those who had received neoadjuvant nivolumab and ipilimumab had a major pathological...

Pages